PT  - JOURNAL ARTICLE
AU  - Dominic L Sykes
AU  - Khaing Thuthu
AU  - Olly I Brown
AU  - Ahalya Parthasarathy
AU  - Michael G Crooks
AU  - Shoaib Faruqi
TI  - Outcomes and characteristics of COVID-19 patients treated with CPAP/ HFNO outside of the Intensive Care setting
AID  - 10.1183/13993003.congress-2021.PA1090
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA1090
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA1090.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA1090.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: CPAP and High Flow Nasal Oxygen (HFNO) have become frequently utilised treatments for COVID-19 patients with hypoxaemic respiratory failure. We observe the outcomes and characteristics of patients treated with CPAP/HFNO on a respiratory ward to gain insight into the utility of these forms of respiratory support in severe COVID-19.Methods: Data were collected prospectively using a standardised protocol from patients who were treated with CPAP/ HFNO on a respiratory ward in a large university hospital. Outcomes of interest included inpatient death, comorbidities, duration of treatment, and physiological parameters prior to treatment.Results: Outcomes for 66 patients (67% Male, Mean age = 68.9 [SD=12.7]) were observed, with overall inpatient mortality of 59% (n=39), rising to 75% (n=36) in those deemed unsuitable for invasive ventilation. Comorbidities were prevalent, with Hypertension (56%), Diabetes Mellitus (32%), and COPD (27%) being the most common. The median duration of CPAP/HFNO in our cohort was 3.5 days (range = 1-24). All patients who were deemed suitable for invasive ventilation survived their admission. CPAP/HFNO was tolerated well in 85% (n=56) of patients.Conclusions: The use of CPAP/HFNO has been widely used in COVID-19 patients deemed unsuitable for mechanical ventilation, as it may incur survival benefit in those where there are limited treatment options. We demonstrate that CPAP/HFNO can be useful in treating severe COVID-19 patients outside of the ICU, however, there remains high mortality in the frail and those deemed unsuitable for mechanical ventilation.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1090.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).